-
Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc. have announced positive top-line data from a pivotal Phase III clinical study for the once-daily, oral CXCR4 antagonist mavorixafor. The trial is assessing the molecule as a treatment for WHIM syndrome (warts, hypogammaglobulinemia, infections, and…
